Stayble Therapeutics (Sweden) Performance
| STABL Stock | SEK 0.57 0.02 3.64% |
The entity has a beta of 0.22, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Stayble Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Stayble Therapeutics is expected to be smaller as well. At this point, Stayble Therapeutics has a negative expected return of -0.4%. Please make sure to validate Stayble Therapeutics' total risk alpha and the relationship between the potential upside and market facilitation index , to decide if Stayble Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Stayble Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 10.9 M | |
| Total Cashflows From Investing Activities | -1000.00 |
Stayble |
Stayble Therapeutics Relative Risk vs. Return Landscape
If you would invest 88.00 in Stayble Therapeutics AB on September 3, 2024 and sell it today you would lose (31.00) from holding Stayble Therapeutics AB or give up 35.23% of portfolio value over 90 days. Stayble Therapeutics AB is generating negative expected returns and assumes 7.104% volatility on return distribution over the 90 days horizon. Simply put, 63% of stocks are less volatile than Stayble, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Stayble Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stayble Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Stayble Therapeutics AB, and traders can use it to determine the average amount a Stayble Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0559
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | STABL |
Estimated Market Risk
| 7.1 actual daily | 63 63% of assets are less volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Stayble Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Stayble Therapeutics by adding Stayble Therapeutics to a well-diversified portfolio.
Stayble Therapeutics Fundamentals Growth
Stayble Stock prices reflect investors' perceptions of the future prospects and financial health of Stayble Therapeutics, and Stayble Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stayble Stock performance.
| Return On Equity | -0.76 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (97.37) % | |||
| Current Valuation | 15.2 M | |||
| Shares Outstanding | 13.85 M | |||
| Price To Book | 2.85 X | |||
| Price To Sales | 213.81 X | |||
| EBITDA | (12.03 M) | |||
| Cash And Equivalents | 42.71 M | |||
| Cash Per Share | 3.09 X | |||
| Total Debt | 850 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 1.43 X | |||
| Cash Flow From Operations | (9.63 M) | |||
| Earnings Per Share | (1.27) X | |||
| Total Asset | 43.64 M | |||
About Stayble Therapeutics Performance
Assessing Stayble Therapeutics' fundamental ratios provides investors with valuable insights into Stayble Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Stayble Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Stayble Therapeutics AB develops injectable treatment for chronic low back pain triggered by disc degeneration. Stayble Therapeutics AB is based in Gothenburg, Sweden. Stayble Therapeutics is traded on Stockholm Stock Exchange in Sweden.Things to note about Stayble Therapeutics performance evaluation
Checking the ongoing alerts about Stayble Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Stayble Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Stayble Therapeutics generated a negative expected return over the last 90 days | |
| Stayble Therapeutics has high historical volatility and very poor performance | |
| Stayble Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (12.09 M) with profit before overhead, payroll, taxes, and interest of 9 K. | |
| Stayble Therapeutics AB has accumulated about 42.71 M in cash with (9.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Stayble Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stayble Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Stayble Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Stayble Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stayble Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Stayble Therapeutics' stock. These opinions can provide insight into Stayble Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Stayble Stock Analysis
When running Stayble Therapeutics' price analysis, check to measure Stayble Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stayble Therapeutics is operating at the current time. Most of Stayble Therapeutics' value examination focuses on studying past and present price action to predict the probability of Stayble Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stayble Therapeutics' price. Additionally, you may evaluate how the addition of Stayble Therapeutics to your portfolios can decrease your overall portfolio volatility.